Supreme Court admits case; no coercive action against Supriya Lifescience directors

Court Stay ObtainedRegulatory & Legal View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹886.20

prior close

₹891.80

announcement price

In-mkt

timing

Nifty Microcap 250market-1.7%+0.1% vs market

Pharmaceuticals peers, median of 172sector-1.6%+0.1% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

-0.2

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-1.7+0.1-1.6+0.1

Next day

-4.2-4.2+0.0-3.5-0.7

-5.8-5.2-0.6-3.7-2.1

-8.4-7.4-1.0-5.3-3.2

-6.3-7.0+0.7-4.1-2.2

-3.8pendingpending-2.3-1.5

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Supriya Lifescience informed exchanges that a matter has been admitted by the Supreme Court and is listed for hearing. The Court has directed no coercive action against the company's directors, officers and officials pending the case. This is a continuation of earlier intimations about the same matter. The case remains sub judice and the company will update exchanges on further developments.

Likely market impact

Interim relief for directors as no coercive action is allowed; final outcome pending and could affect stock sentiment.